Emicizumab prophylaxis in hemophilia A with inhibitors

New England Journal of Medicine

Volumn 377, Issue 9, 2017, Pages 809-818

  Oldenburg, Johannes ^a   Mahlangu, Johnny N ^b   Kim, Benjamin ^c   Schmitt, Christophe ^e   Callaghan, Michael U ^f   Young, Guy ^d   Santagostino, Elena ^g   Krusejarres, Rebecca ^h   Negrier, Claude ⁱ   Kessler, Craig ^j   Valente, Nancy ^c   Asikanius, Elina ^e   Levy, Gallia G ^c   Windyga, Jerzy ^k   Shima, Midori ^l  

^a UNIVERSITY HOSPITAL BONN   (Germany)

^b UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^c GENENTECH INC   (United States)

^d UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^e F HOFFMANN LA ROCHE LTD   (Switzerland)

^f CHILDREN'S HOSPITAL OF MICHIGAN   (United States)

^g FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^h BloodWorks Northwest   (United States)

ⁱ UNIVERSITÉ LYON 1   (France)

^j GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

^k INSTITUTE OF HEMATOLOGY AND TRANSFUSION MEDICINE   (Poland)

^l NARA MEDICAL UNIVERSITY   (Japan)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED PROTHROMBIN COMPLEX; BLOOD CLOTTING FACTOR 8 INHIBITOR; EMICIZUMAB; ALLOANTIBODY; BISPECIFIC ANTIBODY; BLOOD CLOTTING FACTOR; BLOOD CLOTTING FACTOR 7A; BLOOD CLOTTING FACTOR 8; MONOCLONAL ANTIBODY; PROTHROMBIN COMPLEX CONCENTRATES; RECOMBINANT PROTEIN;

ADOLESCENT; ADULT; AGED; ARTHRALGIA; ARTICLE; BLEEDING; CAVERNOUS SINUS THROMBOSIS; CHILD; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; HEADACHE; HEMATOMA; HEMOPHILIA A; HUMAN; IMMUNOGENICITY; INJECTION SITE REACTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SKIN NECROSIS; SUPERFICIAL THROMBOPHLEBITIS; THROMBOTIC THROMBOCYTOPENIC PURPURA; TREATMENT OUTCOME; UPPER RESPIRATORY TRACT INFECTION; BLOOD; CHEMICALLY INDUCED; CLINICAL TRIAL; COMBINATION DRUG THERAPY; HEMORRHAGE; IMMUNOLOGY; MIDDLE AGED; SUBCUTANEOUS DRUG ADMINISTRATION; THROMBOSIS; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTIBODIES, BISPECIFIC; ANTIBODIES, MONOCLONAL, HUMANIZED; BLOOD COAGULATION FACTORS; CHILD; DRUG THERAPY, COMBINATION; FACTOR VIIA; FACTOR VIII; HEMOPHILIA A; HEMORRHAGE; HUMANS; INJECTIONS, SUBCUTANEOUS; ISOANTIBODIES; MALE; MIDDLE AGED; RECOMBINANT PROTEINS; THROMBOSIS; YOUNG ADULT;

EID: 85028497303     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1703068     Document Type: Article

References (20)

1. Mannucci PM, Tuddenham EGD. The hemophilias — from royal genes to gene therapy. N Engl J Med 2001;344:1773-9.
2. Witmer C, Young G. Factor VIII inhibitors in hemophilia A: rationale and latest evidence. Ther Adv Hematol 2013;4:59-72.
3. Morfini M. Articular status of haemophilia patients with inhibitors. Haemophilia 2008;14:Suppl 6:20-2.
4. Gringeri A, Mantovani LG, Scalone L, Mannucci PM. Cost of care and quality of life for patients with hemophilia complicated by inhibitors: the COCIS Study Group. Blood 2003;102:2358-63.
5. Monahan PE, Baker JR, Riske B, Sou-cie JM. Physical functioning in boys with hemophilia in the U.S. Am J Prev Med 2011;41:Suppl 4:S360-S368.
6. Kitazawa T, Igawa T, Sampei Z, et al. A bispecific antibody to factors IXa and X restores factor VIII hemostatic activity in a hemophilia A model. Nat Med 2012;18: 1570-4.
7. Sampei Z, Igawa T, Soeda T, et al. Identification and multidimensional optimization of an asymmetric bispecific IgG antibody mimicking the function of factor VIII cofactor activity. PLoS One 2013; 8(2):e57479.
8. Shima M, Hanabusa H, Taki M, et al. Factor VIII–mimetic function of humanized bispecific antibody in hemophilia A. N Engl J Med 2016;374:2044-53.
9. Mahlangu J, Oldenburg J, Callaghan MU, et al. Bleeding events and safety outcomes in patients with hemophilia a with inhibitors: a prospective, multicenter, noninterventional study. Blood 2016;128:3800. abstract.
10. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) adopts consolidated guideline on Good Clinical Practice in the Conduct of Clinical Trials on Medicinal Products for Human Use. Int Dig Health Legis 1997;48:231-4.
11. World Medical Association. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA 2013;310:2191-4.
12. Blanchette VS, Key NS, Ljung LR, Manco-Johnson MJ, van den Berg HM, Srivastava A. Definitions in hemophilia: communication from the SSC of the ISTH. J Thromb Haemost 2014;12:1935-9.
13. Wyrwich KW, Krishnan S, Poon JL, et al. Interpreting important health-related quality of life change using the Haem-A-QoL. Haemophilia 2015;21:578-84.
14. Walters SJ, Brazier JE. Comparison of the minimally important difference for two health state utility measures: EQ-5D and SF-6D. Qual Life Res 2005;14:1523-32.
15. Pickard AS, Neary MP, Cella D. Estimation of minimally important differences in EQ-5D utility and VAS scores in cancer. Health Qual Life Outcomes 2007;5:70.
16. Uchida N, Sambe T, Yoneyama K, et al. A first-in-human phase 1 study of ACE910, a novel factor VIII-mimetic bispecific antibody, in healthy subjects. Blood 2016;127: 1633-41.
17. Adamkewicz J, Muto A, Soeda T, Suzuki S, Kitazawa T. In vitro thrombin generation testing and in vivo venous stasis model for assessing the pro-coagulant effects of FVIII, emicizumab, rFVIIa, and aPCC. Haemophilia 2017;23:Suppl S2: OR37. abstract.
18. Franchini M, Lippi G. Prothrombin complex concentrates: an update. Blood Transfus 2010;8:149-54.
19. Yoneyama K, Schmitt C, Kotani N, et al. Repeated time-to-event modeling to characterize the bleeding-prophylactic efficacy of ACE910, a bispecific antibody to factors IXa and X, in patients with hemophilia A. Clin Pharmacol Ther 2016;99: Suppl:PI-003. abstract.
20. Nogami K, Hanabusa H, Taki M, et al. Updated results of an ongoing long-term phase 1/2 study of emicizumab (ACE910) in hemophilia A patients with or without inhibitors. Haemophilia 2016;22:Suppl 3: 76. abstract.